We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go: Extended investment: £10,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go: Extended investment: Withheld
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Plantwork Systems (PWS) is an eco-conscious, technology company providing sustainable and environmentally friendly solutions to the wastewater treatment industry. It is the developer, owner, and provider of a range of proprietary technologies such as TN-REM, NUTREM®, and the deHoxar Spiral Separator. These products aid in nutrient removal, improved filtration, sludge thickening. This leads to wastewater treatment plants recycling more water, reducing their energy requirements, and minimising water scarcity. The company has generated combined revenues of £1.44 million since July 2017. PWS is seeking funding of up to £1 million, at a pre-money valuation of £6 million. It will use the investment to accelerate its growth and bring more innovative products to the market. 

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £244,865
Liquid supplements are a faster acting and a more efficient way for the body to absorb key active ingredients than taking pills. Our scientists have developed formulations involving leading active ingredients such as collagen in order to create the perfect wellness solution in every bottle. Each LQ bottle is packed full of 9 or more active ingredients all in one easy to drink, daily 50 m bottle.
days to go: Expired investment: £355,000
Qure are an affordable and convenient on-demand healthcare service providing a doctor to users doors within 2 hours, 24/7. The hassle-free healthcare connects individuals with highly-experienced medical practitioners in the local area. 
days to go: Expired investment: £720,000
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph